Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04552535 · ClinicalTrials.gov registry record

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

A clinical trial of Squamous Non-Small Cell Lung Cancer, sponsored by Boehringer Ingelheim.

Completed
Registry status
200
Enrollment target
1
Study location

NCT04552535 is a study of Squamous Non-Small Cell Lung Cancer that has completed, run by Boehringer Ingelheim. The registered enrollment target is 200 participants, below the 227-participant average among 6 other Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04552535, a study of Squamous Non-Small Cell Lung Cancer, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.

Conditions Studied

Squamous Non-Small Cell Lung Cancer

Interventions

  • DRUG Second line (2L) afatinib
  • DRUG Second line chemotherapy

Study Locations (1)

Ohio

  • Cardinal Health Specialty Solutions - Dublin

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2020-05-08
Est. Completion 2020-05-18

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04552535

The ClinicalTrials.gov registry entry for NCT04552535 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 6 other Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (12% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Second line (2L) afatinib is the first listed.

NCT04552535 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04552535 about?

NCT04552535 is a clinical study titled "A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung". This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.

What is the current status of trial NCT04552535?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2020-05-08. Estimated completion is 2020-05-18.

What conditions does trial NCT04552535 study?

This clinical trial studies the following conditions: Squamous Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT04552535?

The interventions under investigation include: Second line (2L) afatinib (DRUG), Second line chemotherapy (DRUG).

Who is sponsoring clinical trial NCT04552535?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04552535 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Non-Small Cell Lung Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.